


CLAIMS

1. A compound of formula (I):



wherein:

- 5 R₁ is H or methyl;
 R₂ and R₃ are both methyl, or R₂ and R₃, together with the carbon atom to which they are attached, are a spirocyclopropyl ring;
 R₄ is methyl or ethyl;
 R₅ is H or methyl;
- 10 or R₄ and R₅, together with the carbon atom to which they are attached, form a C₃-C₄ spiro carbocyclyl;
 or a salt and/or solvate and/or derivative thereof.
- 15 2. The compound according to claim 1 wherein R₁ is H.
3. The compound according to claim 1 wherein R₁ is methyl.
4. The compound according to any one of claims 1 to 3, wherein R₂ and R₃ are a spiro cyclopropyl.
- 20 5. The compound according to any one of claims 1 to 3, wherein R₂ is methyl and R₃ is methyl
6. The compound according to any one of claims 1 to 5, wherein R₄ is methyl.
- 25 7. The compound according to any one of claims 1 to 5, wherein R₄ is ethyl.
8. The compound according to any one of claims 1 to 7, wherein R₅ is H.
- 30 9. The compound according to any one of claims 1 to 7, wherein R₅ is methyl.

10. The compound according to any one of claims 1 to 5, wherein R₄ and R₅, together with the carbon atom to which they are attached, form a spirocyclopropyl.
11. The compound according to any one of claims 1 to 5, wherein R₄ and R₅, together with the carbon atom to which they are attached, form a spirocyclobutyl.
12. The compound according to claim 1 selected from the group consisting of:
 - 5,5-dimethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione;
 - 3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5,5-dimethyl-imidazolidine-2,4-dione;
 - (5R)-5-ethyl-5-methyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl]imidazolidine-2,4-dione;
 - 5,5-dimethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-5-ethyl-5-methyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5-ethyl-5-methyl-imidazolidine-2,4-dione;
 - 5,5-dimethyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-5-ethyl-5-methyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-5-ethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-5-ethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl]imidazolidine-2,4-dione;
 - (5R)-3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5-ethyl-imidazolidine-2,4-dione;
 - (5R)-5-ethyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-dione;
 - 7-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]-5,7-diazaspiro[3.4]octane-6,8-dione;
 - 6-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]-4,6-diazaspiro[2.4]heptane-5,7-dione;

(5S)-5-ethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione
or a salt and/or solvate thereof and/or derivative thereof.

- 5 13. The compound according to claim 1 which is:
5,5-dimethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione.
- 10 14. The compound according to claim 1 which is:
3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5,5-dimethyl-imidazolidine-2,4-dione.
- 15 15. The compound according to claim 1 which is:
(5R)-5-ethyl-5-methyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl]imidazolidine-2,4-dione.
- 20 16. The compound according to claim 1 which is:
5,5-dimethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yloxy)pyrazin-2-yl]imidazolidine-2,4-dione.
- 25 17. The compound according to claim 1 which is:
(5R)-5-ethyl-5-methyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione.
- 30 18. The compound according to claim 1 which is:
(5R)-3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5-ethyl-5-methyl-imidazolidine-2,4-dione.
- 35 19. The compound according to claim 1 which is:
5,5-dimethyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-dione.
20. The compound according to claim 1 which is:
(5R)-5-ethyl-5-methyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-dione.

21. The compound according to claim 1 which is:
(5R)-5-ethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione.
- 5 22. The compound according to claim 1 which is:
(5R)-5-ethyl-3-(5-spiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl)imidazolidine-2,4-dione.
23. The compound according to claim 1 which is:
10 (5R)-3-[5-[(3,3-dimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]-5-ethyl-imidazolidine-2,4-dione.
24. The compound according to claim 1 which is:
(5R)-5-ethyl-3-[5-[(3,3,7-trimethyl-2H-benzofuran-4-yl)oxy]pyrazin-2-yl]imidazolidine-2,4-
15 dione.
25. The compound according to claim 1 which is:
7-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]-5,7-diazaspiro[3.4]octane-6,8-dione.
20
26. The compound according to claim 1 which is:
6-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]-4,6-diazaspiro[2.4]heptane-5,7-dione.
- 25 27. The compound according to claim 1 which is:
(5S)-5-ethyl-3-[5-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrazin-2-yl]imidazolidine-2,4-dione.
28. The compound according to any one of claims 1 to 27 for use as a medicament.
30
29. The compound according to any one of claims 1 to 28 for use in the prophylaxis or treatment of a disease or disorder selected from the group consisting of hearing disorders, schizophrenia, depression and mood disorders, bipolar disorder, substance abuse disorders, anxiety disorders, sleep disorders, hyperacusis and disturbances of loudness perception,
35 Ménière's disease, disorders of balance, and disorders of the inner ear, impulse control disorder, personality disorders, attention-deficit/hyperactivity disorder, autism spectrum

disorders, eating disorders, cognition impairment, ataxia, pain such as neuropathic pain, inflammatory pain and miscellaneous pain, Lewy body dementia and Parkinson's disease.

30. Use of a compound according to any one of claims 1 to 27 in the manufacture of a
5 medicament for the prophylaxis or treatment of a disease or disorder selected from the group consisting of hearing disorders, schizophrenia, depression and mood disorders, bipolar disorder, substance abuse disorders, anxiety disorders, sleep disorders, hyperacusis and disturbances of loudness perception, Ménière's disease, disorders of balance, and disorders of the inner ear, impulse control disorder, personality disorders, attention-deficit/hyperactivity
10 disorder, autism spectrum disorders, eating disorders, cognition impairment, ataxia, pain such as neuropathic pain, inflammatory pain and miscellaneous pain, Lewy body dementia and Parkinson's disease.

31. A method for the prophylaxis or treatment of a disease or disorder selected from the
15 group consisting of hearing disorders, schizophrenia, depression and mood disorders, bipolar disorder, substance abuse disorders, anxiety disorders, sleep disorders, hyperacusis and disturbances of loudness perception, Ménière's disease, disorders of balance, and disorders of the inner ear, impulse control disorder, personality disorders, attention-deficit/hyperactivity disorder, autism spectrum disorders, eating disorders, cognition impairment, ataxia, pain such
20 as neuropathic pain, inflammatory pain and miscellaneous pain, Lewy body dementia and Parkinson's disease which comprises administering to a subject in need thereof an effective amount of a compound according to any one of claims 1 to 27.

32. A pharmaceutical composition comprising a compound according to any one of claims 1
25 to 27 and a pharmaceutically acceptable carrier or excipient.

33. The compound, use, method or composition according to any one of claims 1 to 32, wherein the compound is administered orally.

30 34. The compound, use, method or composition according to any one of claims 1 to 33, wherein the compound is administered at 2 to 400 mg per day, such as 2 to 300 mg per day, especially 5 to 250 mg per day.

35 35. The compound, use, method or composition according to any one of claims 1 to 34, wherein the compound is administered once or twice per day.


36. The compound, use, method or composition according to claim 35 wherein the compound is administered once per day.

37. The compound, use, method or composition according to claim 35 wherein the compound is administered twice per day.


38. The compound, use, method or composition according to any one of claims 1 to 37, wherein the compound is administered for a period of at least three months.

39. The compound, use, method or composition according to any one of claims 1 to 32, wherein the compound is administered orally once or twice per day at 2 to 400 mg per day, such as 2 to 300 mg per day, especially 5 to 250 mg per day.

40. A compound of formula (II) or (XVI):




15



wherein R₁, R₂ and R₃ are as defined in claim 1, X is halo, such as Br.

41. A compound of formula (IV):



wherein R₄ and R₅ are as defined in claim 1, Y is halo, such as Cl.

25